Viridian Therapeutics, Inc. VRDN Accrued interest
Accrued interest at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestPayableCurrent.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s accrued interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s accrued interest?
- Viridian Therapeutics, Inc. (VRDN) reported accrued interest of $385K in Q1 2026.
- How has Viridian Therapeutics, Inc.'s accrued interest changed year-over-year?
- Viridian Therapeutics, Inc.'s accrued interest increased by 150.0% year-over-year, from $154K to $385K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s accrued interest?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s accrued interest has grown at a 114.5% compound annual growth rate (CAGR), from $39K to $385K.
- What does accrued interest mean?
- Interest expense accrued but not yet paid on outstanding debt obligations, based on contractual interest rates and time elapsed.